Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration

ABSTRACT

Purpose: To evaluate aqueous flare levels following intravitreal ranibizumab injection for neovascular age-related macular degeneration (AMD).

Methods: In total, 81 eyes of 79 patients who underwent intravitreal ranibizumab injection for neovascular AMD were included. Aqueous flare was evaluated before pupillary dilatation with Kowa FM-600 laser flare meter at baseline, and 1 day, and 1 month after intravitreal administration of ranibizumab 0.5 mg (0.05 mL).

Results: The mean anterior chamber flare was 10.7 ± 6.8 (range: 1.5–35.4) ph/ms before the injection, 12.5 ± 8.9 (range: 0.3–43) ph/ms on the first day, and 9.9 ± 5.7 (range: 0.2–28.4) ph/ms in the first month. On the first day, a subtle increasing of flare was observed. However, the difference between the mean aqueous flare levels at baseline and postoperative first day and first month was not statistically different (p>0.05).

Conclusions: No significant short-term intraocular inflammation was noted in these eyes receiving ranibizumab for the treatment of neovascular AMD.

Keywords:

• Age-related macular degeneration
• anterior chamber
• aqueous flare
• intravitreal injection
• ranibizumab

DECLARATION OF INTEREST

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Preliminary results of this study were presented in the International Ocular Inflammation Society Congress, November 13–16, 2011, Goa, India.